VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Metrics to compare | VNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −3.3x | −0.5x | |
PEG Ratio | −0.07 | 0.08 | 0.00 | |
Price/Book | −2.5x | 2.1x | 2.6x | |
Price / LTM Sales | 52.6x | 3.5x | 3.1x | |
Upside (Analyst Target) | 304.4% | 27.3% | 46.1% | |
Fair Value Upside | Unlock | 7.8% | 6.9% | Unlock |